Syndax Pharmaceuticals Inc SNDX 深 沪
等待开盘 10-15 09:30:00 美东时间
13.53
-0.420
-3.01%
华盛通- 最 高14.005
- 今 开13.92
- 成交量 304.00万股
- 最 低 13.39
- 昨 收 13.95
- 总市值 12.08亿
- 52周最高 25.59
- 市盈率 静 --
- 换手率 3.40%
- 52周最低 12.99
- 委 比 80.65%
- 总股本 8929.71万
- 历史最高 29.86
- 量 比 1.08
- 振 幅 4.41%
- 历史最低 3.39
- 每 手 1
- 风险率 2.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Syndax Pharmaceuticals Suffers Pipeline Blow
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) announced it will halt the clinical development of axatilimab in idiopathic pulmonary fibrosis (IPF) after the drug missed its primary endpoint in the Phase 2 MAXPIRe trial. The study failed to demonstrate efficacy in reducing the annualized rate of decline ...
10-14 00:24
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $38 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $38 price target.
10-13 18:59
美股夜盘 | Syndax Pharmaceuticals Inc暴泻15.59%，最新股价13.97美元
Syndax Pharmaceuticals Inc急泻15.59%，报13.97美元
10-13 09:44
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
Syndax Pharmaceuticals announced that the Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint of reducing the annualized rate of forced vital capacity (FVC) decline. While axatilimab was well-tolerated with a safety profile similar to placebo, Syndax will not pursue further development of axatilimab in IPF. The drug continues to be studied in trials for chronic graft-versus-host disease (cG...
10-12 20:01
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals granted 9 new employees stock options to purchase up to 213,300 shares under its 2023 Inducement Plan on October 1, 2026. The options vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. Syndax, a biopharmaceutical company advancing innovative cancer therapies, has FDA-approved treatments including Revuforj and Niktimvo, and is conducting clinical trials to further its pipe...
10-02 20:01
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals granted 19 new employees stock options for up to 175,000 shares under its 2023 Inducement Plan on September 1, 2026. The options vest over four years, with 25% vesting after the first year and the remaining shares vesting monthly over 36 months, contingent on continued employment. Syndax, a biopharmaceutical company focused on innovative cancer therapies, currently offers FDA-approved treatments including Revuforj and Nikti...
09-04 20:01
Syndax Announces Participation in September Investor Conferences
Syndax Pharmaceuticals announced that its CEO, Michael A. Metzger, and management team will participate in two upcoming investor conferences: the Citi 2026 Biopharma Back to School Conference on September 10, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. Both events will feature fireside chats available via live webcast on the Company's website at www.syndax.com. Syndax is a biopharmaceutical compan...
09-01 11:00
美股大行评级 | 罗斯百货、迪尔股份获多家大行上调目标价；沃尔玛、Advance遭多家大行下调目标价
今日重点评级关注：摩根士丹利：维持Ultragenyx Pharmaceutical"超配"评级，目标价从67美元升至74美元；Truist Securities：维持Solid Biosciences"买入"评级，目标价从16美元升至20美元
08-24 16:40
UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $33
UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $37 to $33.
08-21 23:44
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
